To include your compound in the COVID-19 Resource Center, submit it here.
Novartis’ Sandoz Inc. unit said it plans to launch five biosimilars worldwide by 2020. The planned launches include
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury